Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 20/20 | 0.88 |
| ▸ | LCK | P06239 | 1/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.88 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.88 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.88 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.88 |
| ▸ | EGFR | P00533 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278592 | 0.93 | MAP3K8 (1.00) | MAP3K8LCKCYP3A4RPS6KB1MAPK8 | |
| SCHEMBL4961615 | 0.87 | MAP3K8 (0.82) | MAP3K8MAPKAPK2EGFR | |
| SCHEMBL6071940 | 0.84 | MAP3K8 (1.00) | MAP3K8MAPKAPK2EGFR | |
| SCHEMBL4964645 | 0.84 | MAP3K8 (0.81) | MAP3K8LCKCYP3A4RPS6KB1MAPK8 | |
| SCHEMBL4964129 | 0.83 | MAP3K8 (0.75) | MAP3K8CYP3A4RPS6KB1MAPKAPK2EGFR | |
| SCHEMBL27728235 | 0.83 | MAP3K8 (0.84) | MAP3K8 | |
| SCHEMBL4960489 | 0.83 | MAP3K8 (1.00) | MAP3K8CYP3A4MAPKAPK2EGFR | |
| SCHEMBL6071095 | 0.83 | MAP3K8 (0.72) | MAP3K8CYP3A4RPS6KB1MAPKAPK2EGFR | |
| SCHEMBL27728096 | 0.82 | MAP3K8 (0.78) | MAP3K8CYP3A4RPS6KB1MAPKAPK2EGFR | |
| SCHEMBL27707302 | 0.82 | MAP3K8 (1.00) | MAP3K8CYP3A4RPS6KB1MAPKAPK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888529-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
| WO-2006124692-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | MAP3K8 84/4885LCK 296/4885CYP3A4 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.